Adverse pregnancy outcomes among HIV-positive pregnant women treated with efavirenz-containing antiretroviral drugs: a retrospective cohort study in the Cape Flats
Loading...
Date
2017
Journal Title
Journal ISSN
Volume Title
Publisher
University of the Western Cape
Abstract
The use of efavirenz (EFV) in the first trimester of pregnancy
remains controversial. In South Africa, the use of EFV-containing antiretroviral
therapy (ART) as part of a Fixed Dose Combination (FDC) during the first
trimester of pregnancy started in April, 2013. Literature to date has reported
conflicting outcomes following the use of EFV-containing ART during the first
trimester of pregnancy. The objectives of the study were to determine the
prevalence of adverse pregnancy outcomes among HIV-positive pregnant women
treated with EFV-containing ART and compare these results with those of pregnant
women treated with NVP-containing ART and HIV-negative pregnant women in
resource-limited settings. In addition, the study also aimed to determine the effect
of the time of initiation of ART on the prevalence of adverse pregnancy outcomes.
Description
Doctor Pharmaceuticae - Dpharm
Keywords
Adverse pregnancy outcomes, Antiretroviral drug, Birth defect, Efavirenz, First trimester, HIV, Low birth weight, Nevirapine, Pregnant women, Preterm delivery